Risk factor
High price volatility
Profitability factor
Greatly overvalued vs peers
About
Alar Pharmaceuticals Inc. is a biopharmaceutical firm based in Taiwan, dedicated to creating sustained-release therapeutic agents. Its primary focus lies in addressing central nervous system (CNS) conditions and various chronic illnesses. The company's product pipeline features several investigational drugs. ALA-1000 is currently in Phase II clinical development, targeting opioid use disorder. Its preclinical programs include ALA-1300 and ALA-2000, also for opioid use disorder; ALA-4000, aimed at Parkinson's disease; and ALA-3000, intended for treatment-resistant depression. Established in 2016, the firm operates from its headquarters in Taichung, Taiwan.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.